pCDNA3.1(+)-CMV-bArrestin2-TEV Citations (5)
Originally described in: PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome.Kroeze WK, Sassano MF, Huang XP, Lansu K, McCorvy JD, Giguere PM, Sciaky N, Roth BL Nat Struct Mol Biol. 2015 May;22(5):362-9. doi: 10.1038/nsmb.3014. Epub 2015 Apr 20. PubMed Journal
Articles Citing pCDNA3.1(+)-CMV-bArrestin2-TEV
| Articles |
|---|
| Functional Characterization of Spinocerebellar Ataxia Associated Dynorphin A Mutant Peptides. Lieb A, Thaler G, Fogli B, Trovato O, Posch MA, Kaserer T, Zangrandi L. Biomedicines. 2021 Dec 11;9(12). pii: biomedicines9121882. doi: 10.3390/biomedicines9121882. PubMed |
| Chimeric GPCRs mimic distinct signaling pathways and modulate microglia responses. Schulz R, Korkut-Demirbas M, Venturino A, Colombo G, Siegert S. Nat Commun. 2022 Aug 15;13(1):4728. doi: 10.1038/s41467-022-32390-1. PubMed |
| The novel peptide LCGM-10 attenuates metabotropic glutamate receptor 5 activity and demonstrates behavioral effects in animal models. Malyshev AV, Pavshintcev VV, Mitkin NA, Sukhanova IA, Gedzun VR, Zlobin AS, Doronin II, Babkin GA, Sawyer TK. Front Behav Neurosci. 2024 Feb 7;18:1333258. doi: 10.3389/fnbeh.2024.1333258. eCollection 2024. PubMed |
| Dopamine receptor D2 confers colonization resistance via microbial metabolites. Scott SA, Fu J, Chang PV. Nature. 2024 Apr;628(8006):180-185. doi: 10.1038/s41586-024-07179-5. Epub 2024 Mar 13. PubMed |
Size-reduced DREADD derivatives for AAV-assisted multimodal chemogenetic control of neuronal activity and behavior.
Miyake T, Tanaka K, Inoue Y, Nagai Y, Nishimura R, Seta T, Nakagawa S, Inoue KI, Hasegawa E, Minamimoto T, Doi M.
Cell Rep Methods. 2024 Oct 21;4(10):100881. doi: 10.1016/j.crmeth.2024.100881.
PubMed
Associated Plasmids |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.